In a report released today, Raju Prasad from William Blair maintained a Buy rating on Poseida Therapeutics (PSTX). The company’s shares closed last Wednesday at $10.93.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 15.9% and a 61.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Poseida Therapeutics with a $30.00 average price target.
See today’s analyst top recommended stocks >>
Based on Poseida Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $34.41 million. In comparison, last year the company had a GAAP net loss of $20.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
